Merck's Oral PCSK9
FDA Approves Merck's Lipfendra, a Breakthrough Oral PCSK9 Inhibitor for Cholesterol Management
Anonymous
Key Points
1
Lipfendra (enlicitide) is described as a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors, making it the first oral PCSK9 inhibitor.
2
The FDA approval was helped along by the agency's National Priority Voucher program, indicating the drug's potential public health impact and a faster review process.
3
In CORALreef Lipids, there was a post-hoc data handling adjustment that removed biologically impossible baseline LDL-C values when assessing LDL-C reductions.
4
Merck appears to have outpaced AstraZeneca in securing the first U.S. FDA approval for an oral PCSK9 inhibitor, underscoring a competitive race to bring this therapy to market.
5
Regulators described Lipfendra as a first-of-its-kind pill capable of lowering LDL-C beyond what statins can achieve, signaling a new wave of cholesterol treatment options.
The FDA has approved Lipfendra (enlicitide) as the first oral PCSK9 inhibitor ever brought to market, Reuters reported. The once-daily pill lowers LDL-C — the so-called "bad" cholesterol — in adults with hypercholesterolemia, including those with a hereditary form of the condition called heterozygous familial hypercholesterolemia.
Merck's approval marks a major shift in cholesterol treatment. Until now, PCSK9 inhibitors were only available as injectable drugs. A daily pill could open the door to far more patients who avoid injections — and analysts say peak sales could reach tens of billions of dollars.
How Lipfendra Works as a New Kind of Pill
Lipfendra is a macrocyclic peptide — a small ring-shaped molecule. It blocks a protein called PCSK9, which normally degrades receptors that clear LDL cholesterol from the blood. By stopping PCSK9, the drug lets more receptors work, which lowers LDL levels. It is taken as a 20 mg tablet once a day, Reuters reported.
PCSK9 inhibitors already on the market — like Repatha and Praluent — work the same way but must be injected every two to four weeks. Merck's pill offers the same mechanism without a needle, which doctors say could make it easier for patients to stick with treatment.
Phase 3 Trial Data That Convinced the FDA
The FDA's decision was based on two Phase 3 studies called the CORALreef trials. Both measured LDL-C reductions at 24 weeks compared to a placebo. The results showed meaningful drops in bad cholesterol, according to Reuters. Merck did not immediately disclose the exact percentage reduction in its public statements around approval.
One wrinkle in the data: in the CORALreef Lipids trial, researchers made a post-hoc adjustment. They removed what were called biologically impossible baseline LDL-C values before calculating results. Critics may scrutinize that change, but regulators accepted the analysis and moved forward with approval.
Merck Beats AstraZeneca in a Crowded Race
Merck was not alone in chasing an oral PCSK9 inhibitor. AstraZeneca has been developing its own pill in the same class. But Merck crossed the finish line first, securing U.S. FDA approval ahead of its rival, Reuters reported. The win strengthens Merck's cardiovascular drug portfolio at a time when its cancer drug Keytruda faces looming patent pressure.
The FDA also used its National Priority Voucher program to speed up the review. That designation signals the agency viewed Lipfendra as having significant public health value — not just a commercial win for Merck.
What This Means for the Cholesterol Treatment Market
Statins like atorvastatin have been the backbone of cholesterol treatment for decades. They work well but do not bring LDL low enough for every patient. Injectable PCSK9 inhibitors filled that gap but faced slow adoption — partly because of cost and partly because many patients dislike injections. A once-daily pill could change that, according to Reuters.
Merck executives called the approval "a pivotal moment" for cholesterol management. With a pill format and a first-mover advantage in oral PCSK9 therapy, analysts expect aggressive uptake. Peak sales projections in the tens of billions of dollars put Lipfendra in the same conversation as blockbuster drugs like Keytruda, according to Reuters.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
66
Articles
305
Reach
371
A
AnonymousAuthor